A Phase I Study of Pazopanib in Adult Patients With Liver Cancer

A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients With Hepatocellular Cancer

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00370513

Enrollment

Registered

2006-08-31

Start date

2006-12-06

Completion date

2009-04-08

Last updated

2017-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Hepatocellular

Keywords

pazopanib, liver cancer, hepatocellular cancer

Brief summary

Liver cancer is a good target for anti-angiogenic treatments such as pazopanib. The effect of pazopanib in patients with liver cancer are unknown. This study is designed to evaluate the safety, tolerability and best dose of pazopanib to be given to patient with liver cancer.

Interventions

DRUGpazopanib

Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of advanced liver cancer adequate bone marrow, liver and kidney function * Any local therapy for tumor must have been completed at least 4 weeks prior to enrolling in study

Exclusion criteria

* Pregnant or breastfeeding * Any serious or unstable medical or psychiatric conditions * History of metastases to central nervous system * History of ulcer, inflammatory bowel disease or disease of the gut * History of HIV, or uncontrolled infection * Have had a cardiac condition or stoke during the past 6 months * High blood pressure * Have had a blood clot during the past 6 months * History of bleeding blood vessels

Design outcomes

Primary

Measure	Time frame
Adverse events (AEs) and changes in vital signs and laboratory values. A dose regimen where no more than 1 out of 6 subjects experience a dose-limiting toxicity (DLT) will define the maximum tolerated dose (MTD).	throughout the study

Secondary

Measure	Time frame
Various pharmacokinetic parametersAlpha-fetoprotein (AFP) measurements and scans	throughout the study

Countries

Hong Kong, Taiwan, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026